Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Charles Crawley

Chair TA Committee B

National Institute for Health and Care Excellence

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (16)

Jesus Duque-Afonso

faculty of medicine university of freiburg freiburg germany

GERMANY

View details

Per Ljungman

Karolinska University Hospital

SWEDEN

View details

Didier Blaise

Professor of Medicine

Aix-Marseille University

FRANCE

View details

Jakob R Passweg

Head

University Hospital Basel

SWITZERLAND

View details

Ibrahim Yakoub-Agha

Professeur des Universités - Praticien Hospitalier

Centre Hospitalier Régional Universitaire de Lille

FRANCE

View details

Charles Craddock

University of Birmingham

UNITED KINGDOM

View details

Stephan Mielke

Professor of Hematology and Cell Therapy

Karolinska Institutet

SWEDEN

View details

Zinaida Perić

Associate Professor

University in Rijeka

CROATIA

View details

Charlotte Graham

King’s College London

UNITED KINGDOM

View details

Anjum Khan

University of York

UNITED KINGDOM

View details

Raffaella Greco

Dirigente Medico Senior

Ospedale San Raffaele

ITALY

View details

Aimee Jackson

University of Birmingham

UNITED KINGDOM

View details

Gerard Socie

FRANCE

View details

Cristina CASTILLA LLORENTE

Institut Gustave Roussy

FRANCE

View details

Sylvie Freeman

University of Birmingham

UNITED KINGDOM

View details

Justin Loke

University of Birmingham

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Charles Crawley

Research Interests

Explore related searches

Articles (20)

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

Splenic radiotherapy before allogeneic transplantation for myelofibrosis.

Landscapes of HLA Mismatching in Contemporary Unrelated Haematopoietic Cell Transplantation.

Allogeneic hematopoietic cell transplantation for older patients with Philadelphia-positive acute lymphoblastic leukemia. A study by the Acute Leukemia Working Party of the EBMT.

The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes: a contemporary and comprehensive study from the transplant complications working party of the EBMT.

Impact of donor selection in adverse-risk AML undergoing hematopoietic cell transplantation: A study from the EBMT Acute Leukemia Working Party.

Addition of thiotepa to a busulphan based conditioning regimen does not improve survival in patients allografted for acute myeloid leukaemia and myelodysplasia: Results of the UK impact cosi trial

Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Adenovirus infections after allogeneic hematopoietic cell transplantation in children and adults: a study from the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy

Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS

Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies

BI03 The presence of VEXAS-related <i>UBA1</i> mutation in a patient with myelodysplastic syndrome

HLA Mismatching and Transplant Outcome in the Ptcy Era: A Comprehensive Study By the EBMT Cellular Therapy and Immunobiology Working Party

Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.

Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS

HLA Class I Mismatches Reduce Survival after HCT in the Ptcy Era: A Study By the EBMT Cellular Therapy and Immunobiology Working Party

High Responses Rates with Single Agent Belantamab Mafodotin in Relapsed Systemic AL Amyloidosis

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT

Collaborators (16)

Jesus Duque-Afonso

Per Ljungman

Didier Blaise

Jakob R Passweg

Ibrahim Yakoub-Agha

Charles Craddock

Stephan Mielke

Zinaida Perić

Charlotte Graham

Anjum Khan

Raffaella Greco

Aimee Jackson

Gerard Socie

Cristina CASTILLA LLORENTE

Sylvie Freeman

Justin Loke

Make your next move.